Month: January 2025

The 66th American Society of Hematology (ASH) Annual Meeting was held from December 7–10, 2024, in San Diego, USA. As one of the largest global academic events in hematology, it showcased cutting-edge research and the latest drug development data. At this prestigious conference, Dr. Zhihui Li from Beijing GoBroad Boren Hospital (Dr. Tong Wu ’s team) presented an oral abstract (Abstract 599) investigating the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced natural killer/T-cell lymphoma (NKTCL) and analyzing prognostic factors affecting transplantation outcomes. Hematology Frontier  invited Professor Li to provide in-depth insights into this study.

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7 to 10, 2024, in San Diego, USA. This global event brought together leading experts in hematology to discuss the latest advancements in the field. At the meeting, the team led by Dr. Ruidong Zhang from Beijing Children’s Hospital，Capital Medical University presented significant findings (Abstract O312) on the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL), providing fresh insights and possibilities for future therapies. Hematology Frontier invited Dr. Peijing Qi, the study's lead investigator, to provide an in-depth analysis of the research and its implications for clinical practice.

The 66th American Society of Hematology (ASH) Annual Meeting, held in San Diego from December 7–10, 2024, brought together global hematology experts to discuss the latest research advancements. Among the noteworthy contributions, Dr. Qingxiao Song’s team from the Hematology Medical Center of The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) had three studies selected (O263, P3391, P4777), with two of them earning ASH Abstract Achievement Awards. These studies offer new insights and therapeutic possibilities for chronic graft-versus-host disease (cGVHD). Hematology Frontier invited Dr. Qingxiao Song for an in-depth analysis of these groundbreaking studies.

The 66th American Society of Hematology (ASH) Annual Meeting concluded successfully from December 7 to 10, 2024, in San Diego, USA. As the largest and most comprehensive international academic conference in the field of hematology, ASH attracts numerous experts and scholars worldwide to discuss groundbreaking research and advancements in hematology.At this year’s ASH meeting, the team led by Dr. Bing Xu and Dr. Zhijuan Lin from The First Affiliated Hospital of Xiamen University presented multiple studies, including one oral presentation. Their research covered various topics such as the immune microenvironment of Epstein-Barr Virus-positive diffuse large B-cell lymphoma (EBV+DLBCL), the prognostic relevance of SUVmax in follicular lymphoma (FL), and immune microenvironmental changes in FL patients with early progression. Hematology Frontier had the privilege of interviewing Professor Zhijuan Lin on-site to discuss her team's findings and the latest significant developments in FL research presented at the conference.

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7–10, 2024, in San Diego, USA. As the largest international academic conference in hematology, it showcased cutting-edge research and the latest advancements in drug development, representing the highest level of academic achievement in the field. Severe aplastic anemia (SAA) remains a challenging condition to treat, with a poor prognosis, making it a focal point for research. At this year's ASH meeting, Dr. Fengkui Zhang and his team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences presented a study (Abstract 304) exploring the efficacy of combining the novel thrombopoietin receptor agonist (TPO-RA), Hetrombopag, with immunosuppressive therapy (IST) for treating SAA. The study demonstrated promising results. In an exclusive interview, Hematology Frontier delved into the findings and implications of this research with Professor Zhang. Below is a detailed summary and analysis of the study and interview.